Astrazeneca Stock News

AstraZeneca plc (NASDAQ: AZN ) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2. Data from the pivotal DESTINY-Breast04 Phase 3 trial showed Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) in patients Full story available on Benzinga.com

AstraZeneca said on Tuesday that Leif Johansson would step down following the annual general meeting in 2023 and the search for a chair successor was proceeding well

https://www.investing.com/news/stock-market-news/astrazeneca-chairman-leif-johansson-to-retire-in-2023-2768990

British drug major AstraZeneca is joining with U.S. Technology major Honeywell to develop next-generation respiratory inhalers that use near-zero global warming potential or GWP propellants to treat asthma and chronic obstructive pulmonary disease or COPD. The new inhalers are expected to reduce greenhouse gas emissions of propellant by up to 99.9 percent compared to the current inhaler propellant

(Reuters) COVID-19 vaccine maker AstraZeneca said on Tuesday its non-executive chairman Leif Johansson will retire following the annual general meeting next year, and that the search for a successor has begun.

Honeywell (HON) is collaborating with AstraZeneca (AZN) to develop and bring to market next-generation respiratory inhalers that use near-zero global warming potential ((GWP))

Roche (RHHBY) is closing patent infringement suit against AstraZeneca (AZN) related to the medicine Ultomiris, Fierce Pharma reported.AstraZeneca inherited the rare disease

AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-l

The pharmaceutical companies said Enhertu demonstrated meaningful survival improvement in patients with breast cancer compared with physician's choice of chemotherapy.

COVID-19 vaccine maker AstraZeneca said on Tuesday its non-executive chairman Leif Johansson will retire following the annual general meeting next year, and that the search for a successor has begun.

TOKYO: Japan''s Nikkei share average tumbled more than 2% on Tuesday, extending losses to a fourth session, as sentiment soured further following an escalation in tensions around Ukraine. The Nikkei slid 2.17% to 26,327.90 by the midday break. The broader Topix slumped 1.76% to 1,877.01, also heading for a fourth straight session of losses. Only 11 of the Nikkei''s 225 constituent stocks rose, with one flat and the others falling. Healthcare was the sole sector to rise, pulled up by drugmaker Daiichi Sankyo surging about 10%, after positive results for the Erhertu cancer drug it co-developed with AstraZeneca. Consumer sectors were the worst performers, with basic materials and tech also suffering sizable losses. Tokyo shares end lower Japanese markets will be closed on Wednesday for a public holiday, putting market players in the mind to close out positions, traders said. Russian President Vladimir Putin ordered the deployment of troops to two breakaway regions in eastern Ukraine after recognising them as independent on Monday, accelerating a crisis the West fears could unleash a major war. "Risks around Ukraine have taken a turn for the worse, but at the same time, most of the potential near-term bad news has probably already been priced in by the market," said Makoto Kikuchi, chief executive of Myojo Asset Management.

First HER2-low metastatic breast cancer phase-III results for AstraZeneca and Daiichi Sankyos Enhertu offer potential to redefine how the disease is classified and treated The post Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients with HER2-low metastatic breast cancer appeared first on Express Pharma .

Daiichi Sankyo Co. posted its biggest gain in more than 18 months after the breast cancer drug its developing with AstraZeneca Plc helped patients with advanced disease live longer, potentially expanding treatment options for the most common cancer in women.

Daiichi Sankyo Co. posted its biggest gain in more than 18 months after the breast cancer drug its developing with AstraZeneca Plc helped patients with advanced disease live longer, potentially expanding treatment options for the most common cancer in women.

Enhertu was shown to cause a ''clinically meaningful improvement'' in the survival rates of people with metastatic breast cancer.